QNCX · As filed with the SEC
Quince Therapeutics income statement, by quarter
The statement as Quince Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS · USD, except per-share amounts
| USD, except per-share amounts | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | 5,461,000 | 6,845,000 | — | 8,083,000 |
| Acquired in-process research and development | 59,000,000 | — | — | — |
| General and administrative | 16,626,000 | 4,267,000 | — | 3,281,000 |
| Goodwill impairment charge | — | — | — | 0 |
| Gain on Orphai Acquisition | (1,305,000) | — | — | — |
| Intangible asset impairment charge | 0 | 67,808,000 | — | — |
| Fair value adjustment for contingent consideration | 0 | (64,330,000) | — | 2,066,000 |
| Total operating expenses | 79,782,000 | 14,590,000 | — | 13,430,000 |
| Loss from operations | (79,782,000) | (14,590,000) | — | (13,430,000) |
| Fair value adjustment for debt | 0 | 12,168,000 | — | (549,000) |
| Fair value adjustment for warrants | — | — | — | 291,000 |
| Fair value adjustment for warrants | 4,507,000 | 31,116,000 | — | — |
| Warrant issuance costs | (874,000) | — | — | (42,000) |
| Interest income | 584,000 | 160,000 | — | 300,000 |
| Other (expense) income, net | 152,000 | 1,719,000 | — | (58,000) |
| Net loss before income tax expense | (75,413,000) | 30,573,000 | — | (13,488,000) |
| Income tax benefit (expense) | (75,000) | 5,339,000 | — | 46,000 |
| Net income (loss) | (75,488,000) | 35,912,000 | — | (13,442,000) |
| Other comprehensive loss: | ||||
| Foreign currency translation adjustments | (355,000) | (1,135,000) | — | 125,000 |
| Unrealized loss on available-for-sale securities | 0 | (5,000) | — | 12,000 |
| Total comprehensive loss | (75,843,000) | 34,772,000 | — | (13,305,000) |
| Net loss per share - basic (in USD per share) | (12.31) | 3.60 | — | (0.25) |
| Net loss per share - diluted( (in USD per share) | (12.31) | 2.88 | — | (0.25) |
| Weighted average shares of common stock and in-substance common stock outstanding - basic (in shares) | 6,132,845 | 9,120,267 | — | 53,951,371 |
| Weighted average shares of common stock and in-substance common stock outstanding - diluted (in shares) | 6,132,845 | 9,190,354 | — | 53,951,371 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.